Ho Yi-Jung, Lin Yueh-Min, Huang Yen-Chi, Shi Bingyang, Yeh Kun-Tu, Gong Zhiyuan, Lu Jeng-Wei
School of Pharmacy, National Defense Medical Center, Taipei, Taiwan.
Department of Pathology, Changhua Christian Hospital, Changhua, Taiwan; Department of Medical Technology, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli, Taiwan.
Biochem Biophys Res Commun. 2017 Dec 9;494(1-2):173-180. doi: 10.1016/j.bbrc.2017.10.060. Epub 2017 Oct 15.
To investigate the relationship between YY1AP1 and various clinicopathological features of colon adenocarcinoma (COAD), we conducted immunohistochemical (IHC) analyses of human tissue microarrays. We found that YY1AP1 protein expression was significantly higher in tumor tissue of the colon and liver, and was significantly lower in tumor tissue of the kidney. An analysis that employed the SurvExpress database indicated that increased expression of YY1AP1 mRNA was significantly associated with the overall survival of COAD patients. To clarify the validity of YY1AP1 or PCNA as determined by the IHC analysis was performed on 59 paired samples from COAD and adjacent normal tissue. Statistically significant differences of immunoreactivity for YY1AP1 or PCNA protein expression was observed between COAD tissue and adjacent normal tissue. High protein expression levels of YY1AP1 and PCNA were also found to be significantly correlated with M-class and distant metastasis. We also determined that YY1AP1 was correlated with PCNA expression in COAD samples, and Kaplan-Meier survival curves indicated that YY1AP1 protein expression was significantly associated with poor survival. Finally, a univariate analysis demonstrated that YY1AP1 protein expression was related to YY1AP1 score, and multivariate analysis revealed that the YY1AP1 protein expression level was an independent risk factor of overall COAD survival. Taken together, our findings indicate that YY1AP1 expression plays an important role in the tumorigenesis and progression of COAD and could serve as a clinical prognostic indicator for COAD.
为了研究YY1AP1与结肠腺癌（COAD）各种临床病理特征之间的关系，我们对人组织芯片进行了免疫组织化学（IHC）分析。我们发现，YY1AP1蛋白表达在结肠和肝脏的肿瘤组织中显著更高，而在肾脏的肿瘤组织中显著更低。一项利用SurvExpress数据库的分析表明，YY1AP1 mRNA表达增加与COAD患者的总生存期显著相关。为了阐明通过免疫组织化学分析确定的YY1AP1或PCNA的有效性，我们对来自COAD和相邻正常组织的59对样本进行了检测。在COAD组织和相邻正常组织之间观察到YY1AP1或PCNA蛋白表达的免疫反应性存在统计学显著差异。还发现YY1AP1和PCNA的高蛋白表达水平与M分期和远处转移显著相关。我们还确定在COAD样本中YY1AP1与PCNA表达相关，并且Kaplan-Meier生存曲线表明YY1AP1蛋白表达与较差的生存率显著相关。最后，单因素分析表明YY1AP1蛋白表达与YY1AP1评分相关，多因素分析显示YY1AP1蛋白表达水平是COAD总体生存的独立危险因素。综上所述，我们的研究结果表明YY1AP1表达在COAD的肿瘤发生和进展中起重要作用，并可作为COAD的临床预后指标。
